Voyageur Pharmaceuticals Ltd · TSXV:VM
Voyageur Pharmaceuticals — Investor Presentation (November 2019)
28 slides from Voyageur Pharmaceuticals's investor presentation, November 2019
Slide 1: Voyageur Pharmaceuticals Ltd & ImagingX Pharmaceuticals Inc
VOYAGEUR PHARMACEUTICALS LTD & Imaging Pharmaceuticals Inc From the Earth to the Bottle Pharmaceutical Barite & Iodine for Radiographic Contrast Suspension Products: X-Ray, MRI, CT Scan Applications www.voyageurminerals.ca
Slide 2: Forward looking statement
• This presentation, its contents and any related oral presentations are confidential and the property of Voyageur Pharmaceutical Minerals (“VM” or the “Company”) and have been prepared by the Company solely for the use at the meeting where this document is presented and may not be taken away, repro
Slide 3: Corporate Structure
Corporate Structure VOYAGEUR PHARMACEUTICALS VM-TSXV VOYAGEUR INDUSTRIAL IMAGINGX PHARMACEUTICALS VOYAGEUR INC MINERALS • A 50/50 revenue sharing joint venture Utah USA corporation • Frances Creek (Barium Sulfate) company, between Voyageur and Chief • ULI Project (iodine, bromine • Pedley Mountain (
Slide 4: Share Structure
Voyageur Is Poised to Bring Low Cost Pharmaceuticals to our Canadian and world Customers Share Structure august 4th, 2019 Issued and Outstanding: 62,497,872 Fully Diluted: 91,469,840
Slide 5: Pharmaceutical Barite & Iodine for the Health Care Industry
Pharmaceutical Barite & Iodine for the Health Care Industry Voyageur Pharmaceutical (“VM“) or (“the Company”) (VM:TSX.V) anticipates near term cash flow from its JV company ImagingX. ImagingX is a barium and iodine radiographic contrast manufacturing & sales company. After cash flow commences VM wil
Slide 6: Projects Based in Canada and the USA
Projects Based in Canada and the USA Barium Sulfate ImagingX : Chief Medical Projects GMP Sterile Manufacturing Plants Frances Creek Pedley Mountain Calgary, Alberta Jubilee Mountain Mississauga, Ontario Iodine Lithium Mineral Brine Deposits Lithium King Project ULI Project
Slide 7: The Competitive Advantage
Imagine… if you were the only medical company in the free world that had their own 100% long term supply of two minerals that are vital to a specific medical procedure. This medical procedure is used worldwide, everyday, in every country on the planet… The The market is projected to be valued intern
Slide 8: What are Barium and Iodine Radiocontrast Agents?
What are Barium Radiographic contrast: Radiographic contrast agents are and Iodine substances used to enhance the visibility of internal structures in X-ray-based imaging techniques such as computed tomography, Radiocontrast projectional radiography, and fluoroscopy. Agents? Unique: ImagingX is movi
Slide 9: Net Revenue Joint Venture signed with Chief Medical Supplies Ltd
Net Revenue Joint Venture signed with Chief Medical Supplies Ltd TURN KEY BARIUM AND IODINE CONTRAST PRODUCTION FACILITY, FAST TRACK TO CASH FLOW
Slide 10: Corporate Flow Chart
Voyageur Phase 1: Import API barium sulfate Pharmaceutical Minerals & iopamidol Phase 2: Produce API barium sulfate & Corporate Chief Medical iopamidol from mineral deposits Flow Chart Formulate Manufacture ImagingX Pharmaceuticals Sales Distribution 50% revenue share
Slide 11: ImagingX at the Regulatory Submission Stage
ImagingX is at the Regulatory Submission Stage on the Pharmaceutical Pipeline
Slide 12: Steps To Full Integration & Market Domination
Steps To Full Integration & Market Domination A Cash Flow Barite Imports Establish Market & B Cash Flow Iopamidol Imports From the Earth to Economics Establish Market & Economics the Bottle in four C Barite Mine Production steps 7300% Ingredient Cost Advantage D Iopamidol Production Lowest Cost Iodi
Slide 13: Highlights of the Contrast Market
High revenue market and only two main competitors in North America Highlights Aging population = more health care required of the Contrast media usage has increased 40% in the last 5 years alone Contrast Market Radiographic contrast products are one of the highest consumed Healthcare products on the
Slide 14: The Most Valuable Commodity is Human Health
The Most Valuable Commodity is Human Health… not Minerals, Metals or Oil. The contrast imaging market is poised for high future growth rate. The population over age 85 is going to double in 20 years. This is a global phenomenon - the baby boomer generation is a major market driver.
Slide 15: Our Partner: Chief Medical Supply Inc.
Our Partner: Chief Medical Supply Inc. Chief has one of the largest pharmaceutical manufacturing plants in North America. Multiple sterile 500 bottle per minute bottle lines at the GMP Mississauga plant. Turn key manufacturing of iodine & barium contrast production ready for production upon Canada H
Slide 16: Contrast Products Simple Ingredients
Contrast Products Simple Ingredients • Barium Contrast main ingredients: • Barite • Starch • Sugar • Flavoring • Water • Iodine Contrast Main Ingredients: • Iodine • Organic Binder • Water
Slide 17: 14 New Product Lines to Launch in 2019/2020
Low Density Barium Smoothie: SmoothX High Density Liquid Barium: MultiXthick Low Density Liquid barium: MultiXthin 14 New Powdered Low Density Barium: MultiXba Product High Density Barium Powder: HDX Lines to Modified Barium Swallow: BarX - Thin Launch in BarX – Low 2019/2020 BarX – Medium BarX – Th
Slide 18: Barium Sulfate Contrast & Industrial Barite Sales Forecast
Barium Sulfate Contrast & Industrial Barite Sales Forecast Year 1 2 3 4 5 6 7 8 CapX -$ 12,000,000 Barium Sulfate Mined 3000 3000 3000 3000 5000 5000 5000 Estimated Tonnes Contrast sold per year 20 50 200 500 1000 1500 2000 revenue contrast voyageur $ 347,932.87 $ 869,832.17 $ 3,479,328.69 $ 8,698,3
Slide 19: Iodine Contrast Manufacturing Forecast
Iodine Contrast Manufacturing Forecast Iodine Contrast Manufacturing CapX -$ 50,000,000 2 3 4 5 6 7 8 Estimated Tonnes sold per year 50 100 200 500 1000 1500 2200 Total revenue $ 9,906,250 $ 19,812,500 $ 39,625,000 $ 99,062,500 $ 198,125,000 $ 297,187,500 $ 435,875,000 Total Cost $ 3,500,000 $ 7,000
Slide 20: Combined Cash Flow of Barium Contrast, Barite, & Iodine Sales
Combined Cash Flow of Barium Contrast Sales, Industrial Barite Sales, & Iodine Sales Corporate Cash Flow 1 2 3 4 5 6 7 8 Total Corporate Revenue $ 22,174,183 $ 35,432,332 $ 57,104,329 $ 120,260,822 $ 235,521,643 $ 340,782,465 $ 485,668,287 Total Corporate Costs $ 5,300,000 $ 8,800,000 $ 15,800,000 $
Slide 21: Voyageur Success Will Provide Security for API Minerals in North America
80 percent of the active pharmaceutical ingredients (APIs) used to make drugs in the Voyageur Success United States are said to come from China and other countries like India. (source: U.S.-China Will Provide Economic and Security Review Commission) Security for API Only three FDA approved Iopamidol
Slide 22: Time Line
ImagingX Pharmaceuticals 2019 2020 Milestones Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Import Barium Sulfate 1st order Completed Formulation Completed Health Canada Registration Submitted Canada Diagnostics Script Testing Health Canada Registration Approval Commence marketing and sales in Canada Europe Registration
Slide 23: Target Markets with Government Health Insurance
Target Markets with Government Health Insurance: North America, Brazil, Argentina, Costa Rica, Panama, Colombia, South Africa, Europe, Russia, Israel, Turkey, Jordon, Qatar, Kuwait, UEA, Malaysia, Singapore, Hong Kong, China, Japan, Philippines, Brunei, South Korea, Australia & New Zealand.
Slide 24: Conclusion
Joint venture with experienced pharmaceutical company Lucrative high revenue high margin markets Mine production to give ImagingX a highly competitive advantage Conclusion Fully Integrated - Control of all cost inputs Control of entire supply chain from the ground to the bottle = Low risk on price f
Slide 25: Executive Officers & Directors ImagingX
Dr. Merle E. Olson, D.V.M., M.SC., Co-Founder, Director, Research & Business Development, Chief Medical Supply Ltd. Director ImagingX Dr. Olson attended the University of Regina receiving a BSc in Chemistry and Biology in 1975. He then attended the University of Western Ontario where he received a M
Slide 26: Board of Directors
Brent Willis, CEO, Director CEO of Voyageur Pharmaceuticalminerals Charles Littlejohn, Director, Audit Committee, Mr. Littlejohn graduated from the Western University with a Bachelor of Arts degree and solid background in chemistry, physics and geology. He has considerable experience in PGMs in Onta
Slide 27: Executive Officers Voyageur
Brent Willis, B.Sc.Eng, CEO Brent Willis has over 30 years of experience successfully leading, managing and advancing complex Canadian and international projects in the mining, energy and in R&D industries. Brent lead two mining projects from discovery/exploration through to production/cash flow. A
Slide 28: For more information please contact
For more information Pleasecontact: Steve Livingston V.P.Finance (403) 471-1659 steve@voyageurminerals.ca
Voyageur Pharmaceuticals — Investor Presentation (November 2019) on 6ix